Patient characteristics and mortality by ethnicity: N = 546.
| CHARACTERISTICS | ETHNICITY | P VALUE | |
|---|---|---|---|
| INDIGENOUS (N=323) | OTHER (N = 223) | ||
| Men, n (%) | 185 (57) | 170 (76) | < .001 |
| Median (IQR) age, y | 43 (37–49) | 47 (41–52) | < .001 |
| Taking HAART while at clinic, n (%) | 280 (87) | 198 (89) | .699 |
| Median (IQR) initial CD4 count, cells/μL | 300 (170–450) | 380 (220–530) | .002 |
| Median (IQR) initial VL, HIV RNA copies/mL | 196 (35–16 531) | 133 (35–24 922) | .616 |
| Median (IQR) time taking HAART while at clinic, mo | 27 (10–46) | 23 (5–45) | .109 |
| Median (IQR) total time taking HAART, mo | 71 (31–140) | 95 (44–164) | .010 |
| VL suppression within 1 y of HAART, n (%) | 128 (40) | 101 (45) | .314 |
| Mortality | |||
| • All-cause, n (%) | 45 (14) | 18 (8) | .035 |
| -Incidence rate per 100 PYRs | 6.25 | 4.02 | .113 |
| • HIV-related, n (%) | 18 (6) | 4 (2) | .027 |
| -Incidence rate per 100 PYRs | 2.50 | 0.89 | .063 |
HAART—highly active antiretroviral therapy, IQR—interquartile range, PYRs—person-years, VL—viral load.